Without a doubt, efforts to fight COVID-19 have dominated the flow of money into the biopharma industry through nonprofit collaborations and grants, accounting for 87% and 85% of the 2020 totals, respectively.

Out of the 590 bio/nonprofit deals tracked by BioWorld this year, a total of $7.18 billion has been recorded, but 283 deals valued at $6.24 billion are directly focused on providing therapies for the pandemic. Likewise, of the 430 grants worth $9.3 billion so far in 2020, 117 of them worth $7.9 billion are funding work on therapeutics and vaccines tackling the SARS-CoV-2 virus that causes COVID-19.

A large chunk of this funding has arrived since the start of July: $4.49 billion, or 62%, through 54 bio/nonprofit partnerships; and $4.9 billion, or 52%, through 49 grants.

Both bio/nonprofit deals and grants have reached levels significantly beyond what was seen during the full year of 2019 when there were 545 bio/nonprofit collaborations valued at $5.18 billion and 346 grants valued at $2.18 billion.

BioWorld’s database of biopharma deals with nonprofit and government entities, as well as grants awarded to the industry, are updated through late August and can be found within BioWorld Snapshots.

No Comments